Tisungane Mvalo, Hillary M Topazian, Portia Kamthunzi, Jane S Chen, Isobel Kambalame, Pilirani Mafunga, Noel Mumba, Msandeni Chiume, Khadija Paseli, Gerald Tegha, Wiza Kumwenda, J Brett Heimlich, Graham Ellis, Nigel Key, Satish Gopal, Irving Hoffman, Kenneth I Ataga, Kate D Westmoreland
INTRODUCTION: Sickle cell disease (SCD) is among the most common inherited hematologic diseases in sub-Saharan Africa (SSA). Historically, hydroxyurea administration in SSA has been restricted due to limited region-specific evidence for safety and efficacy. METHODS: We conducted a prospective observational cohort study of pediatric patients with SCD in Malawi. From January 2015 to November 2017, hydroxyurea at doses of 10-20 mg/kg/day was administered to children with clinically severe disease (targeted use policy)...
November 2019: Pediatric Blood & Cancer